Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Ash 2022 – the sickle cell race hots up
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
An expensive new haemophilia gene therapy hits the US
The approval is good for CSL, and better for Uniqure.
Ash 2022 preview – Argenx’s expansion plans come into focus
Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.
Ash 2022 preview – waiting for Editas
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.
Syncona sets its sights on a gene therapy turnaround
But, with Applied Genetic Technologies Corporation, can lightning strike a third time?
ESGCT 2022 – Sangamo strengthens its case in Fabry
The group looks like the gene therapy contender to beat, but that is not saying much.
